Journal Scans
Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03
Neoadjuvant Chemoradiotherapy Offers DFS, RFS Advantage in Locally Advanced Rectal Cancer
MS Roh, LH Colangelo, MJ O'Connell, G Yothers, M Deutsch, CJ Allegra, MS Kahlenberg, L Baez-Diaz, CS Ursiny, NJ Petrelli, N Wolmark
20090821
2009 Sept 21
J Clin Oncol
Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03
J Clin Oncol. 2009 Sept 21; Epub ahead of print, MS Roh, LH Colangelo, MJ O'Connell, G Yothers, M Deutsch, CJ Allegra, MS Kahlenberg, L Baez-Diaz, CS Ursiny, NJ Petrelli, N Wolmark
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Chemoradiotherapy plus surgery is the standard of care for patients with resectable rectal cancer. Although several clinical trials have evaluated adjuvant and neoadjuvant therapy in these patients, the optimal dosage and timing of therapy has not been established. The National Surgical Adjuvant Breast and Bowel Project R-03 (NSABP R-03) study was a phase III trial designed to investigate the effect of preoperative and postoperative chemoradiotherapy on overall survival (OS) and disease-free survival...
